Single-cell multi-omics reveals elevated plasticity and stem-cell-like blasts relevant to the poor prognosis of KMT2A-rearranged leukemia
C. Chen, W. Yu, F. Alikarami, Q. Qiu, C.-h. Chen, J. Flournoy, P. Gao, Y. Uzun, L. Fang, Y. Yu, Q. Zhu, K. Wang, C. Libbrecht, A. Felmeister, I. Rozich, Y.-y. Ding, S. P. Hunger, H. Wu, P. A. Brown, E. M. Guest, D. M. Barrett, K. M. Bernt, K. Tan
Abstract
Infant ALL is a devastating malignancy caused by rearrangements of the KMT2A gene (KMT2A-r) in approximately 70% of patients. The outcome is dismal and younger age at diagnosis is associated with increased risk of relapse. To discover age-specific differences and critical drivers that mediate the poor outcome in KMT2A-r ALL, we subjected KMT2A-r leukemias and normal hematopoietic cells from patients of different ages to multi-omic single cell analysis using scRNA-Seq, scATAC-Seq and snmC-Seq2. We uncovered the following critical new insights: Leukemia cells from infants younger than 6 months have a greatly increased lineage plasticity and contain a hematopoietic stem and progenitor-like (HSPC-like) population compared to older infants. We identified an immunosuppressive signaling circuit between the HSPC-like blasts and cytotoxic lymphocytes in younger patients. Both observations offer a compelling explanation for the ability of leukemias in young infants to evade chemotherapy and immune mediated control. Our analysis also revealed pre-existing lymphomyeloid primed progenitor and myeloid blasts at initial diagnosis of B-ALL. Tracking of leukemic clones in two patients whose leukemia underwent a lineage switch documented the evolution of such clones into frank AML. These findings provide critical insights into KMT2A-r ALL and have potential clinical implications for targeted inhibitors or multi-target immunotherapy approaches. Beyond infant ALL, our study demonstrates the power of single cell multi-omics to detect tumor intrinsic and extrinsic factors affecting rare but critical subpopulations within a malignant population that ultimately determines patient outcome.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single cell mRNA signals reveal a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia
Eleonora Khabirova, Laura Jardine, … Sam Behjati·Nature MedicinePeer-reviewed·Mar 14, 2022
- CD180 identifies chemoresistant stem-like blasts and reveals a KMT2A-driven vulnerability in acute myeloid leukaemia
Madonna M. Eltoukhy, Alexander Winton, … Karen Keeshan·bioRxiv·Apr 27, 2026
- Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups
Alina Hartmann, Lorenz Bastian, … Claudia Dorothea Baldus·HemaSpherePeer-reviewed·Feb 1, 2026
- Leukaemia cell intrinsic and extrinsic factors cooperate to facilitate the survival and proliferation of KMT2A-rearranged B-ALL in the CNS niche.
Alasdair Duguid, Camille Malouf, … Katrin Ottersbach·bioRxiv·Dec 3, 2024
- A Distinct Alternative mRNA Splicing Profile Identifies the Oncogenic CD44 Transcript Variant 3 in KMT2A-Rearranged Pediatric T-cell Acute Lymphoblastic Leukemia Cells
Amanda Ramilo Amor, Sabina Enlund, … Frida Holm·Experimental HematologyPeer-reviewed·Jan 9, 2025
- Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease
Hongwei Ren, Natalina Elliott, … Anastasios Karadimitris·bioRxiv·Jan 22, 2025